Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Zhejiang Huahai Pharmaceutical Co Additional Paid-In Capital?

Zhejiang Huahai Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥1,156 Mil) but then stayed the same from Dec. 2023 (¥1,156 Mil) to Mar. 2024 (¥0 Mil).

Zhejiang Huahai Pharmaceutical Co's annual additional paid-in capital declined from Dec. 2021 (¥1,153 Mil) to Dec. 2022 (¥1,106 Mil) but then increased from Dec. 2022 (¥1,106 Mil) to Dec. 2023 (¥1,156 Mil).

Zhejiang Huahai Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Zhejiang Huahai Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Huahai Pharmaceutical Co Additional Paid-In Capital Chart

Zhejiang Huahai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

968.72

835.74

1,153.11

1,105.54

1,155.69

Zhejiang Huahai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	1,155.92	-	1,155.69	-

Zhejiang Huahai Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zhejiang Huahai Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zhejiang Huahai Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Huahai Pharmaceutical Co Ltd (SHSE:600521) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

Economic Development Zone, Xunqiao Town, Linhai, Taizhou, Zhejiang, CHN, 317024

Website

http://www.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co Ltd provides formulations, active pharmaceutical ingredients, and intermediates in China and internationally. The company also offers pril products, including captopril, enalapril, and lisinopril.

Executives

Chen Bao Hua	Director
Shang Fei	senior management
Du Jun	Director
Su Yan	Director
Chen Dun Yuan	senior management
Li Hong	Director
Guo Si Jia	senior management
Li Min	senior management
Xu Bo	senior management
Wang Jie	senior management
Chen Qi Mao	senior management
Zhang Hong	senior management
Zhang Mei	senior management
Zhu Yong Hua	Directors, senior managers
Wang Yi Hua	senior management

Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Headlines

No Headlines